A new first in class drug getting close to approval to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies…. 

Amylin and Eli Lilly announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTAA® (exenatide) injection added to Lantus® (insulin glargine)…. 

Amylin and Lilly announced the results of another study, comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy….

Data from nearly 1,100 patients in DURATION-1, -2 and -3 trials showed BYDUREON was well-tolerated….

New clinical study shows patients with Type 2 diabetes may be able to tolerate higher doses of metformin using GLUMETZA…. 

Steve, Andrew and I are in Orlando at the ADA 70th Scientific Sessions and although things are just getting started there is already news in the diabetes sector. Lilly has agreed to co-brand their Humulin insulin line with Walmart, the world’s largest retailer. Beginning in mid-September, Lilly’s Humulin brand of …

Look for our Special Edition on the ADA’s 70th Scientific Sessions Symposium this Tuesday!

2010 Product Spotlight Our once-a-year special edition of Product Spotlight is now available. Follow this link to the 2010 Product Spotlight to check out the latest products advancing diabetes care.

African Americans have higher levels of glycated hemoglobin (HbA1c) than whites given the same blood glucose concentrations, and the difference is greater as glucose levels go up. Findings could affect the way physicians use hemoglobin A1c to test for diabetes in blacks…. 

Although the liver is often overlooked in diabetes, even newly-diagnosed cases carry a substantial risk of serious hepatic damage, researchers found….